EMA Reassures Safety of Novartis Flu Vaccine
No evidence that Fluad vaccine caused deaths in Italy, says EMA.
EMA has reported that there is no evidence that the flu vaccine (Fluad) made by Swiss drugmaker, Novartis, caused deaths in Italy after a review by the agency’s Pharmacovigilance Risk Assessment Committee (PRAC).
On November 27, 2014, two batches of the vaccine were suspended by Italian regulators as a precautionary step following the death of four elderly people (two women and two men aged between 67 and 87) after they were given the vaccine. PRAC has reassured EU member states that these cases are not related to the administration of the vaccine.
Fluad is authorized in the EU for use in the elderly, particularly those with multiple illnesses and who are at a higher risk of health complications. Approximately 4 million doses of the drug were distributed as part of a current flu vaccination campaign in Italy. Other countries, including Austria, Germany, and Spain, have also used Fluad in their annual flu vaccination campaigns.
Source: EMA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
